

1 **Recovery and discharge time between remimazolam**
2 **tosylate and propofol in hysteroscopy anesthesia: a**
3 **randomized controlled study**

4

5

6 Xiangyi Lin¹, Shengjie Chen¹, Huiyan Liang¹

7

8 ¹ Department of Anesthesiology, Maternal and Child Health Hospital of Shunde Foshan, Shunde

9 Women and Children's Hospital of Guangdong Medical University, Foshan 528300,

10 Guangdong, China

11

12 Corresponding Author:

13 Shengjie Chen ¹

14 Department of Anesthesiology, Maternal and Child Health Hospital of Shunde Foshan, Shunde

15 Women and Children's Hospital of Guangdong Medical University, NO.3 Baojian Road Street,

16 Foshan, Guangdong, 528300, China

17 Email address: sdsilence@hotmail.com

18

19 **Abstract**

20 **Background.** Hysteroscopy is considered the gold standard for the evaluation and treatment of
21 uterine and endometrial lesions, but the operation is accompanied by severe pain, so it needs to
22 be performed under anesthesia. Currently, a new sedative drug, remimazolam tosylate, can be

23 used in digestive endoscopy and bronchoscopy. We will study its effect on hysteroscopy and its
24 impact on patient recovery time and hospital discharge time.

25 **Methods.** Ninety-five patients undergoing hysteroscopy were randomly divided into two groups
26 and received an initial dose of 0.2 mg/kg remimazolam tosylate (R group) and an initial dose of 2
27 mg/kg propofol (P group) as anesthetics during the examination. The primary end point was
28 anesthesia recovery time (the time required for the patient's MOAA/S score to reach 5 from the
29 cessation of drug use) and hospital discharge time (the time required for the patient's PADS
30 score to reach 9 from the cessation of drug use). Secondary endpoints were first-dose sedation
31 success rate, incidence of hypotension, and injection pain.

32 **Results.** Age($P = 0.825$), height($P = 0.174$), weight($P = 0.667$) and ASA grade ($P = 0.972$) were
33 not significantly different between the two groups. The recovery time in the R group was
34 significantly shorter than that in the P group ($P = 0.019$), and the data kurtosis in the R group
35 was higher than that in the P group (1.19 vs -0.56), but there was no significant difference in the
36 time to hospital discharge ($P = 0.696$). There was no significant difference in the success rate of
37 the first dose of sedation between the two groups ($P = 0.362$), but the incidence of hypotension
38 during anesthesia ($P = 0.001$) and the incidence of injection pain ($P = 0.001$) in the R group was
39 significantly lower than those in P group.

40 **Conclusions.** Remimazolam tosylate is suitable for hysteroscopy anesthesia and can reduce
41 intraoperative hypotension and injection pain during the examination, a more optimal dosage or
42 target-controlled infusion model still needs to be further explored.

43 **Introduction**

44 Hysteroscopy is considered to be the gold standard for evaluating and managing uterine and
45 endometrial lesions (van Hanegem et al. 2016; Wang et al. 2021), but cervical dilation and
46 endometrial curettage are accompanied by severe pain(Riemma et al. 2020). Therefore, most
47 hysteroscopies are performed under anesthesia. The most commonly used sedative drug is

48 propofol due to its fast effect(Yu et al. 2019), easy titration, and short half-life, and can also
49 reduce postoperative nausea and vomiting(Schraag et al. 2018). But its large impact on
50 hemodynamics, no specific antagonists, and accumulation after long-term infusion have been its
51 significant adverse effects in clinical application. As a novel ultra-short-acting benzodiazepine
52 sedative drug, remimazolam tosilate has been successfully used as a sedative in
53 bronchoscopy(Jia et al. 2021) and gastrointestinal endoscopy(Rex et al. 2018). It is designed to
54 be rapidly hydrolyzed in the body by ubiquitous tissue esterases to an inactive carboxylic acid
55 metabolite(Kilpatrick et al. 2007). Compared with the existing benzodiazepines, it has a faster
56 onset of action, a shorter and predictable duration of sedation, and outstanding advantages in
57 short-term anesthesia and operation.

58 This study hopes to provide patients with more comfort and shorten treatment time by analyze
59 and comparing the differences in recovery time, hospital discharge time and injection pain
60 indicators between remimazolam tosilate and propofol in anesthesia for hysteroscopy.

61 **Materials & Methods**

62 **Study Design and Participants**

63 This study is a single-center, parallel randomized controlled study, which was approved by the
64 Medical Research Ethics Committee of Shunde Women and Children's Hospital of Guangdong
65 Medical University (Maternal and Child Health Hospital of Shunde Foshan) (registration
66 number:2020055) and registered on Chictr.org (Date of Registration:15/07/2021, Registration
67 number:ChiCTR2100048738). The study protocol followed the CONSORT and related clinical
68 guidelines. All patients participating in the study signed written informed consent of participation
69 and publication.

70 Inclusion criteria for this study: 1. planning to undergo hysteroscopy without endotracheal
71 intubation; 2. aged 18-50 years; 3. American Society of Anesthesiologists (ASA) Physical Status
72 rating I-II. Exclusion criteria: 1. Underweight or overweight (BMI \geq 30 or $<$ 18.5); 2. Anemia

73 (HGB \leq 90g/L); 3. Severe liver and kidney dysfunction; 4. History of sedative abuse and mental
74 illness; 5. Pregnancy or Within 3 months of breastfeeding; 6. Those who intend to undergo
75 spinal anesthesia during examination and operation and those who refuse to participate in this
76 study.

77 **Randomization and Blinding**

78 In this study, the block randomization method was adopted, and R software was used to
79 generate a random sequence based on 4 patients as a block, and the allocation ratio is 1:1. The
80 results were put into opaque envelopes. After the patients signed the informed consent, the
81 researchers unsealed the corresponding envelopes, and allocated the patients. Enter the
82 remimazolam group (R group) and propofol group (P). The study was blinded to the follow-up
83 staff.

84 **Research intervention**

85 All patients received intravenous anesthesia, and patient monitor (iPM8, Mindray Biomedical
86 Electronics Co., Ltd., Shenzhen, China) was used to measure non-invasive blood pressure,
87 SpO₂, ECG and RESP during anesthesia and recovery. After monitoring and venous catheter
88 placement, the initial dose of remimazolam tosylate (Jiangsu Hengrui Pharmaceutical Co., Ltd.,
89 China) in R group was 0.2 mg/kg, followed by infusion at a rate of 1 mg/kg*hr, and an additional
90 0.1 mg/kg remimazolam was given for body movement during the examination The rescue dose
91 was given no more than once every 5 minutes; the initial dose of propofol (Zhejiang Nhwa
92 Pharmaceutical Co., Ltd., China) in P group was 2 mg/kg, followed by infusion at a rate of 8
93 mg/kg*hr, and an additional 1 mg/kg propofol was given to those who experienced body
94 movement during the examination. The rescue dose was given no more than once every 5
95 minutes. At the end of the examination, flurbiprofen axetil (Grand Life Sciences(Wuhan) Co.,
96 Ltd., China) 50 mg was administered intravenously for postoperative analgesia.

97 **Sample size and statistical analysis**

98 In a pilot study of hysteroscopy using propofol and remimazolam(Zhang et al. 2021), patients
99 spent 5.44 minutes (remimazolam group) and 6.3 minutes (propofol group) in the PACU, with a
100 standard deviation of 1.45 . A sample size of 45 participants per group was calculated with a
101 significance level of 0.05 ($\alpha = 0.05$), a strength of 80% ($\beta = 0.20$), and a dropout rate of 10%.
102 Statistical analysis was performed using SPSS Statistics 25.0 (SPSS Inc., Chicago, IL).
103 Normality test in SPSS statistics software was used for data analysis to determine whether the
104 data were in accordance with a normal distribution. Normally distributed continuous variables
105 are presented as the mean \pm standard deviation and were analyzed using Student's t test. The
106 Mann-Whitney U test was used for non-normally distributed continuous variables. Categorical
107 variables are expressed as a frequency (percentage) and were analyzed using the Pearson chi-
108 square test. The Wilcoxon Signed-Rank test was used to compare continuous variables. A p
109 value < 0.05 was considered to indicate statistical significance.

110 **Data Measurement and Acquisition**

111 Demographic data including age, height, weight, and American Society of Anesthesiologists
112 (ASA) rating were recorded for all cases. The main endpoints of the study were the patient's
113 recovery time from anesthesia (the time required for the subject's MOAA/S(Chernik et al. 1990)
114 score to be 5 points since stopping the use of remimazolam or propofol) and the time to hospital
115 discharge (the time required for the subject's PADS(Palumbo et al. 2013) score to express 9
116 points since stopping the use of remimazolam or propofol). The secondary endpoints were the
117 success of the first dose of sedation (1 minute after the administration of the initial dose of the
118 drug, the eyelashes of the patient were stimulated with a cotton swab, and the sedation was
119 considered successful if there was no reflex), the occurrence of hypotension (the blood pressure
120 during anesthesia decreased by more than 20% compared with the systolic blood pressure
121 during the fully awake period or the systolic blood pressure decreased by more than 20%. If the
122 systolic blood pressure drops to ≤ 80 mmHg, hypotension is considered to be present) and
123 injection pain occurs (when the initial dose of drug is given, involuntary retraction of the limb on

124 the injection side or the patient complains of pain in the limb on the injection side is considered
 125 to be pain).

126 Results

127 From July 28, 2021 to September 2, 2021, a total of 155 patients were included in this study,
 128 and 14 cases were excluded due to reasons such as high or low BMI, anemia, patients
 129 receiving assisted reproductive technology or breastfeeding. 46 cases were excluded and
 130 withdrawn due to patients or family members refusing to participate in the study or incomplete
 131 relevant information. A total of 95 patients were finally analyzed in this study (Fig.1).

132 Demographic data are detailed in Table 1, age ($P = 0.825$), height ($P = 0.174$), weight ($P = 0.667$)
 133 and ASA grade ($P = 0.972$) were not significantly different between the two groups.

134 Figure 1: Flow Diagram

135 Table 1:

136 Demographic data (N = 95).

137 All data are expressed as means \pm SD.

Parameters	Groups		t/ χ^2 Value	Df	Significance (P)	Cohen's d/ Phi
	Remimazolam (n=48)	Propofol (n=47)				
Age (year)	32.56 \pm 6.687	32.26 \pm 6.829	0.222	93	0.83	0.044
Height (cm)	157.10 \pm 3.910	158.23 \pm 4.124	-1.371	93	0.17	-0.281
Weight (Kg)	55.98 \pm 5.208	56.45 \pm 5.340	-0.432	93	0.67	-0.089
ASA I/II (n)	43/5	42/5	0.001	1	0.97	0.005

138 As for the primary endpoint, the recovery time from anesthesia in group R was significantly
 139 shorter than that in group P ($P = 0.019$), and the data kurtosis in group R was higher than that in

140 group P(1.19 vs -0.56), but there was no significant difference in the time to hospital discharge
 141 ($P = 0.696$). In secondary endpoints, there was no significant difference in the success rate of the
 142 first dose of sedation between the two groups ($P = 0.362$), but the incidence of hypotension
 143 during anesthesia ($P = 0.001$) and the incidence of injection pain ($P = 0.001$) in group R were
 144 significantly lower than those in group P. (Table 2)

145 **Table2:**

146 **Measurement data (N = 95).**

147 All data are expressed as means \pm SD.

Parameters	Groups		t/ χ^2 Value	Df	Significa nce (P)	Cohen's d/ Phi
	Remimazola m(n=48)	Propofol (n=47)				
Anesthesia recovery time(min)	6.23 \pm 1.547	7.09 \pm 1.932	-2.386	93	0.019	-0.491
Discharge time(min)	89.58 \pm 18.66 9	91.23 \pm 22.23 5	-0.392	93	0.696	-0.804
First dose sedation success(n)	44(91.7%)	46(97.9%)	1.834	1	0.362	0.601
Hypotension(n)	10(20.8%)	26(55.3%)	12	1	0.001	3.364
Injection pain(n)	6(12.5%)	32(68.1%)	30.572	1	0.001	5.529

148 **Discussion**

149 Through this study, it can be found that remimazolam tosylate is used as the initial dose of 0.2
 150 mg/kg in hysteroscopy anesthesia, which has a sedative success rate not inferior to that of
 151 propofol, and the average recovery time is shorter and more concentrated. Suggesting that
 152 when it is used for hysteroscopic anesthesia, patients need to stay in the PACU for a shorter
 153 time, and the drug metabolism is more predictable, which is beneficial to reduce the burden on

154 PACU doctors and nurses and improve turnaround efficiency. The lower incidence of
155 intraoperative hypotension in patients taking concomitant remimazolam tosilate may be a
156 potential benefit of remimazolam, because intraoperative hypotension caused by anesthetic
157 drugs has been shown to be associated with various postoperative organ dysfunction and
158 adverse outcomes(Wesselink et al. 2018). In addition, the less incidence of injection pain may
159 give remimazolam tosilate an advantage in special patients (eg, children)(Nyman et al. 2005).
160 This study did not find that remimazolam tosilate was associated with the shortening of hospital
161 discharge time, which may be due to the limitations of the design of this study, for example, this
162 study was a single-center study with a small sample size, and no propensity scoring or weighted
163 statistics were performed on patients' preoperative fasting time or individual nutritional status.

164 **Conclusions**

165 Remimazolam tosilate is suitable for hysteroscopy anesthesia.
166 Remimazolam tosilate can reduce intraoperative hypotension and injection pain during
167 examination sedation.
168 Recovery time may be further shortened with specific antagonist flumazenil.
169 More optimal dosage or target-controlled infusion model still needs to be further explored.

170 **Acknowledgements**

171 The author thanks the anesthetist nurses for their dedication to patient observation and data
172 collection

173 **Declarations**

174 The data that supports the findings of this study are available within supplementary material.
175 No potential competing interest was reported by the authors.
176 The authors received no financial support for the research, authorship, or publication of this
177 article.

178 Xiangyi Lin and Shengjie Chen wrote the main manuscript text, Huiyan Liang collected and
179 counted all the clinical data, all authors reviewed the manuscript.

180 **References**

- 181 Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, and Siegel
182 JL. 1990. Validity and Reliability of the Observer's: Assessment of Alertness/Sedation
183 Scale: Study with: Intravenous Midazolam. *Journal of Clinical Psychopharmacology* 10.
184 Jia Z, Ren LX, Fan YT, and Tan ZM. 2021. [Observation of effective dosage of remimazolam
185 tosilate used for moderate-to-deep sedation in fiberoptic bronchoscopy]. *Zhonghua yi*
186 *xue za zhi* 101:813-816. 10.3760/cma.j.cn112137-20200901-02524
- 187 Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman
188 PL, Collins H, Waszczak BL, and Tilbrook GS. 2007. CNS 7056: A Novel Ultra–short-
189 acting Benzodiazepine. *Anesthesiology* 107:60-66.
190 10.1097/01.anes.0000267503.85085.c0
- 191 Nyman Y, von Hofsten K, Georgiadi A, Eksborg S, and Lönnqvist PA. 2005. Propofol injection
192 pain in children: a prospective randomized double-blind trial of a new propofol
193 formulation versus propofol with added lidocaine. *BJA: British Journal of Anaesthesia*
194 95:222-225. 10.1093/bja/aei156
- 195 Palumbo P, Tellan G, Perotti B, Pacilè MA, Vietri F, and Illuminati G. 2013. Modified PADSS
196 (Post Anaesthetic Discharge Scoring System) for monitoring outpatients discharge. *Ann*
197 *Ital Chir* 84:661-665.
- 198 Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, Barish CF, Pruitt R, Cash
199 BD, Quirk D, Tiongco F, Sullivan S, and Bernstein D. 2018. A phase III study evaluating
200 the efficacy and safety of remimazolam (CNS 7056) compared with placebo and
201 midazolam in patients undergoing colonoscopy. *Gastrointestinal Endoscopy* 88:427-
202 437.e426. <https://doi.org/10.1016/j.gie.2018.04.2351>

- 203 Riemma G, Schiattarella A, Colacurci N, Vitale SG, Cianci S, Cianci A, and De Franciscis P.
204 2020. Pharmacological and non-pharmacological pain relief for office hysteroscopy: an
205 up-to-date review. *Climacteric* 23:376-383. 10.1080/13697137.2020.1754388
- 206 Schraag S, Pradelli L, Alsaleh AJO, Bellone M, Ghetti G, Chung TL, Westphal M, and Rehberg
207 S. 2018. Propofol vs. inhalational agents to maintain general anaesthesia in ambulatory
208 and in-patient surgery: a systematic review and meta-analysis. *BMC Anesthesiology*
209 18:162. 10.1186/s12871-018-0632-3
- 210 van Hanegem N, Prins MMC, Bongers MY, Opmeer BC, Sahota DS, Mol BWJ, and
211 Timmermans A. 2016. The accuracy of endometrial sampling in women with
212 postmenopausal bleeding: a systematic review and meta-analysis. *European Journal of*
213 *Obstetrics & Gynecology and Reproductive Biology* 197:147-155.
214 <https://doi.org/10.1016/j.ejogrb.2015.12.008>
- 215 Wang C, Feng Y, Zhou W-J, Cheng Z-J, Jiang M-Y, Zhou Y, and Fei X-Y. 2021. Screening and
216 identification of endometrial proteins as novel potential biomarkers for repeated
217 implantation failure. *PeerJ* 9:e11009. 10.7717/peerj.11009
- 218 Wesselink EM, Kappen TH, Torn HM, Slooter AJC, and van Klei WA. 2018. Intraoperative
219 hypotension and the risk of postoperative adverse outcomes: a systematic review.
220 *British Journal of Anaesthesia* 121:706-721. <https://doi.org/10.1016/j.bja.2018.04.036>
- 221 Yu J, Xiang B, Song Y, Chen H, Li Y, and Liu C. 2019. ED50 of propofol in combination with
222 low-dose sufentanil for intravenous anaesthesia in hysteroscopy. *Basic & Clinical*
223 *Pharmacology & Toxicology* 125:460-465. <https://doi.org/10.1111/bcpt.13280>
- 224 Zhang X, Li S, and Liu J. 2021. Efficacy and safety of remimazolam besylate versus propofol
225 during hysteroscopy: single-centre randomized controlled trial. *BMC Anesthesiology*
226 21:156. 10.1186/s12871-021-01373-y
- 227




Figure 1